Clinical DevelopmentsThe FDA cleared INDs for ADI-001 in systemic lupus erythematosus, systemic sclerosis, and ANCA-associated vasculitis.
Financial PerformanceThe company has a solid cash position of $224.1MM.
Innovative TherapiesAdicet’s ADI-270, a CD70-targeting CAR γδ T cell, demonstrated strong anti-tumor activity as well as a lower inflammatory profile.